StreetInsider.com News Articles

OptimizeRX (OPRX) PT Lowered to $20 at Lake Street

Fri, 06 Mar 2026 08:55:36 -0500

Lake Street analyst Eric Martinuzzi lowered the price target on OptimizeRX (NASDAQ: OPRX) to $20.00 (from $24.00) while maintaining a Buy rating.

OptimizeRX (OPRX) PT Lowered to $11 at B.Riley

Fri, 06 Mar 2026 08:07:20 -0500

B.Riley analyst Kyle Bauser lowered the price target on OptimizeRX (NASDAQ: OPRX) to $11.00 (from $28.00) while maintaining a Buy rating.

OptimizeRX (OPRX) PT Lowered to $17 at Stifel After Flattish Q4 Revenue

Fri, 06 Mar 2026 07:25:15 -0500

Stifel analyst David Grossman lowered the price target on OptimizeRX (NASDAQ: OPRX) to $17.00 (from $21.00) while maintaining a Buy rating.

The analyst commented, "4Q revenue in-line (flattish y/y) reflecting slower spend by large pharma (industry-wide MFN dislocation); EPS beat (+$0.21 y/y) on higher margins (channel mix, messaging mix/specialty drugs, $3mn y/y opx decline). NRR retention (LTM) declined 400-500bp y/y and q/q reflecting lower pharma spend including 4Q buy-ups.2026 revenue guide (+2%) lowered well below consensus (+12.5%) reflecting MFN uncertainty and lower managed services revenue (~$10mn in 2025), though guide assumes improvement as year progresses. Visibility 15-20% lower than beginning 2025,

OptimizeRX (OPRX) PT Lowered to $17 at Stifel After Flattish Q4 Revenue

Fri, 06 Mar 2026 07:25:15 -0500

Stifel analyst David Grossman lowered the price target on OptimizeRX (NASDAQ: OPRX) to $17.00 (from $21.00) while maintaining a Buy rating.

OptimizeRX (OPRX) PT Lowered to $10 at Stephens

Fri, 06 Mar 2026 06:54:28 -0500

(Updated - March 6, 2026 6:54 AM EST)

Stephens analyst Jeff Garro lowered the price target on OptimizeRX (NASDAQ: OPRX) to $10.00 (from $17.00) while maintaining a Equal Weight rating.

The analyst commented: "revenue beat, favorable channel mix (GM +660 BPs y/y), and OpEx discipline. For FY26, OPRX decreased revenue guidance by 8% (soft pharma marketing budgets), but management remained confident on customer engagement levels that should translate to more budget unlock in 2Q26 and 2H26. EBITDA margins are forecasted to come down slightly y/y, but the foundation is set for expansion over time; OPRX won't forecast the same product / channel

OptimizeRX (OPRX) PT Lowered to $10 at Stephens

Fri, 06 Mar 2026 06:54:28 -0500

(Updated - March 6, 2026 6:54 AM EST)

Stephens analyst Jeff Garro lowered the price target on OptimizeRX (NASDAQ: OPRX) to $10.00 (from $17.00) while maintaining a Equal Weight rating.

UPDATE – OptimizeRx Reports Strong Fourth Quarter and Full Year 2025 Financial Results

Thu, 05 Mar 2026 17:04:00 -0500

- Q4 revenue of $32.2 million

- Q4 gross profit increased 9% year-over-year to $24.1 million

- Q4 net income and adjusted EBITDA hit records at $5.0 million and $12.0 million, respectively

- Updating 2026 revenue guidance to $109-$114 million and adjusted EBITDA guidance to $21-$25 million

- Paid off an incremental $2 million in principal from term loan during Q4

- Q4 revenue of $32.2 million

- Q4 gross profit increased 9% year-over-year to $24.1 million

- Q4 net income and adjusted EBITDA hit records at $5.0 million and $12.0 million, respectively

- Updating 2026 revenue guidance to $109-$114 million and adjusted EBITDA guidance to $21-$25 million

- Paid off an incremental $2 million in principal from term loan during Q4

- Q4 revenue of $32.2 million

- Q4 gross profit increased 9% year-over-year to $24.1 million

- Q4 net income and adjusted EBITDA hit records at $5.0 million and $12.0 million, respectively

- Updating 2026 revenue guidance to $109-$114 million and adjusted EBITDA guidance to $21-$25 million

- Paid off an incremental $2 million in principal from term loan during Q4

- Q4 revenue of $32.2 million

- Q4 gross profit increased 9% year-over-year to $24.1 million

- Q4 net income and adjusted EBITDA hit records at $5.0 million and $12.0 million, respectively

- Updating 2026 revenue guidance to $109-$114 million and adjusted EBITDA guidance to $21-$25 million

- Paid off an incremental $2 million in principal from term loan during Q4

click here.

Optimizerx Corporation (OPRX) Tops Q4 EPS by 29c

Thu, 05 Mar 2026 16:11:28 -0500

Optimizerx Corporation (NASDAQ: OPRX) reported Q4 EPS of $0.51, $0.29 better than the analyst estimate of $0.22. Revenue for the quarter came in at $32.2 million versus the consensus estimate of $31.46 million.

GUIDANCE:

Optimizerx Corporation sees FY2026 revenue of $109-114 million, versus the consensus of $121 million.

For earnings history and earnings-related data on Optimizerx Corporation (OPRX) click here.

Form 8-K OptimizeRx Corp For: Mar 05

Thu, 05 Mar 2026 16:10:00 -0500

si-local-file:///var/storage/secattach/20260305/26118950.html

Form 8-K OptimizeRx Corp For: Mar 05

Thu, 05 Mar 2026 16:10:00 -0500

si-local-file:///var/storage/secattach/20260305/26118950.html

OptimizeRx Reports Strong Fourth Quarter and Full Year 2025 Financial Results

Thu, 05 Mar 2026 16:01:00 -0500

- Q4 revenue of $32.2 million

- Q4 gross profit increased 9% year-over-year to $24.1 million

- Q4 net income and adjusted EBITDA hit records at $5.0 million and $12.0 million, respectively

- Updating 2026 revenue guidance to $109-$114 million and adjusted EBITDA guidance to $21-$25 million

- Paid off an incremental $2 million in principal from term loan during Q4

- Q4 revenue of $32.2 million

- Q4 gross profit increased 9% year-over-year to $24.1 million

- Q4 net income and adjusted EBITDA hit records at $5.0 million and $12.0 million, respectively

- Updating 2026 revenue guidance to $109-$114 million and adjusted EBITDA guidance to $21-$25 million

- Paid off an incremental $2 million in principal from term loan during Q4

OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, will hold a conference call on Thursday, March 5, 2026, at 4:30 p.m. Eastern Time to discuss its results for the fourth quarter period ended December 31, 2025. The financial results will be issued in a press release prior to the call.

OptimizeRx management will host the call, followed by a question-and-answer period. Details for the conference call can be found

OptimizeRx Sets Fourth Quarter and Full Year 2025 Financial Results Conference Call for March 5, 2026, at 4:30 p.m. ET

Thu, 05 Feb 2026 08:00:00 -0500

WALTHAM, Mass., Feb. 05, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, will hold a conference call on Thursday, March 5, 2026, at 4:30 p.m. Eastern Time to discuss its results for the fourth quarter period ended December 31, 2025. The financial results will be issued in a press release prior to the call.

OptimizeRx management will host the call, followed by a question-and-answer period. Details for the conference call can be found

OptimizeRx and Experian Collaborate to Improve Privacy-Safe Identity Resolution in Healthcare Marketing

Wed, 07 Jan 2026 08:00:00 -0500

Life science marketers will be able to better measure the exposed audiences for a more complete, accurate, and transparent view of campaign engagement and effectiveness

WALTHAM, Mass., Jan. 07, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life science companies reach and engage healthcare professionals (HCPs) and patients, today announced at CES 2026 a data collaboration with Experian, a leading global data and technology company. This integration maps OptimizeRx Micro-Neighborhood^® audiences to Experian’s identity graph, enabling seamless onboarding and curated audience activation, delivering a transparent,

OptimizeRx and Experian Collaborate to Improve Privacy-Safe Identity Resolution in Healthcare Marketing

Wed, 07 Jan 2026 08:00:00 -0500

Life science marketers will be able to better measure the exposed audiences for a more complete, accurate, and transparent view of campaign engagement and effectiveness

Form 4/A OptimizeRx Corp For: Dec 23 Filed by: Silvestro Stephen L

Tue, 23 Dec 2025 17:43:00 -0500

si-local-file:///var/storage/secattach/20251223/25778276.html

Form 4/A OptimizeRx Corp For: Dec 23 Filed by: Silvestro Stephen L

Tue, 23 Dec 2025 17:43:00 -0500

si-local-file:///var/storage/secattach/20251223/25778276.html

Form 4 OptimizeRx Corp For: Dec 23 Filed by: Silvestro Stephen L

Tue, 23 Dec 2025 16:55:00 -0500

si-local-file:///var/storage/secattach/20251223/25777831.html